<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://pharmadevicenews.com/darwin-biotech-reports-early-als-functional-and-nfl-signals-from-randomised-phase-1-alt001-study/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-31T05:19:30+00:00</news:publication_date>
      <news:title>Darwin Biotech reports early ALS functional and NfL signals from randomised Phase 1 ALT001 study</news:title>
      <news:keywords>ALT001, Beijing, Beijing Tiantan Hospital, Capital Medical University, Clearwater, Darwin Biotech, NEALS, Network of Excellence for ALS, Wang Yu, Weiqi Chen, Yilong Wang</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/ALT001-Shows-Early-Promise-in-ALS-e1793423901343.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/gemelli-biotech-highlights-85-patient-study-linking-intestinal-sulfide-overproduction-to-distinct-gene-expression-changes/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-31T05:15:25+00:00</news:publication_date>
      <news:title>Gemelli Biotech highlights 85-patient study linking intestinal sulfide overproduction to distinct gene-expression changes</news:title>
      <news:keywords>American Society for Microbiology, Cedars-Sinai, Gemelli Biotech, IBS-Smart, Juliana de Freitas Germano, Mark Pimentel, mSystems, REIMAGINE, Ritesh Agarwal, Trio-Smart</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/Gemelli-Biotech-Gut-Gene-Infographic-e1793423679772.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/avenzo-therapeutics-to-present-first-orion-1-phase-1-data-for-selective-cdk4-inhibitor-avzo-023/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-31T05:09:42+00:00</news:publication_date>
      <news:title>Avenzo Therapeutics to present first ORION-1 Phase 1 data for selective CDK4 inhibitor AVZO-023</news:title>
      <news:keywords>Allorion Therapeutics, Avenzo Therapeutics, AVZO-021, AVZO-023, ORION-1, San Antonio, San Antonio Breast Cancer Symposium</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/Avenzo-ORION-1-Data-Spotlight-e1793423320691.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/setpoint-medical-completes-first-boston-implant-of-fda-approved-rheumatoid-arthritis-neurostimulation-system/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-31T04:14:12+00:00</news:publication_date>
      <news:title>SetPoint Medical completes first Boston implant of FDA-approved rheumatoid arthritis neurostimulation system</news:title>
      <news:keywords>Beth Israel Deaconess Medical Center, Boston, Brian J. Stout, Joshua P. Aronson, Massachusetts, Murthy V. Simhambhatla, RESET-RA, SetPoint Medical, SetPoint System, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/Vagus-Nerve-Implant-Medical-News-Infographic-e1793419988207.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/transcode-therapeutics-has-advanced-ttx-mc138-into-phase-2a-so-why-is-it-exploring-a-sale-or-strategic-partnership/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-31T04:08:40+00:00</news:publication_date>
      <news:title>TransCode Therapeutics has advanced TTX-MC138 into Phase 2a, so why is it exploring a sale or strategic partnership?</news:title>
      <news:keywords>Natera Inc., Philippe P. Calais, PRE-I-SPY, Quantum Leap Healthcare Collaborative, Signatera, TransCode Therapeutics Inc., TTX-MC138, Tungsten Advisors, Zdravka Medarova</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/TransCode-Biotech-Licensing-News-Banner-e1793419657739.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/can-ascletis-asc30-compete-with-established-oral-glp-1-treatments/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-31T04:02:42+00:00</news:publication_date>
      <news:title>Can Ascletis ASC30 compete with established oral GLP-1 treatments?</news:title>
      <news:keywords>ASC30, Ascletis Pharma Inc., AURORA-1, AURORA-2, European Medicines Agency, Jinzi Jason Wu, United States Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/Pharma-Device-News_-ASC30-Clinical-Update-e1793419314996.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/preservative-free-ketamine-gets-fda-approval-as-nrx-pharmaceuticals-targets-us-hospital-supply/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T19:29:59+00:00</news:publication_date>
      <news:title>Preservative-free ketamine gets FDA approval as NRx Pharmaceuticals targets US hospital supply</news:title>
      <news:keywords>Nephron Pharmaceuticals, NRx Pharmaceuticals, NRX-100, U.S. Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/Preservative-free-ketamine-injection-vials-e1793388266679.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/sabirnetug-trial-failure-forces-acumen-pharmaceuticals-to-reassess-alzheimers-drug-development-strategy/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T19:19:41+00:00</news:publication_date>
      <news:title>Sabirnetug trial failure forces Acumen Pharmaceuticals to reassess Alzheimer’s drug development strategy</news:title>
      <news:keywords>ACU193, Acumen Pharmaceuticals, ALTITUDE-AD, Halozyme Therapeutics, JCR Pharmaceuticals, Sabirnetug, U.S. Food and Drug Administration</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/10/Brain-Scans-e1793387890333.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/edison-scientific-signs-pfizer-agreement-to-deploy-kosmos-ai-scientist-across-pharmaceutical-rd/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T05:49:11+00:00</news:publication_date>
      <news:title>Edison Scientific signs Pfizer agreement to deploy Kosmos AI scientist across pharmaceutical R&amp;D</news:title>
      <news:keywords>Edison Scientific, FutureHouse, Kosmos, Pfizer Inc., Sam Rodriques, San Francisco, Spark Capital, Springer Nature, Triatomic Capital</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/hsg-has-taken-control-of-peiertech-but-why-is-medical-grade-nitinol-attracting-private-equity-investment/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T05:45:13+00:00</news:publication_date>
      <news:title>HSG has taken control of PeierTech, but why is medical-grade nitinol attracting private equity investment?</news:title>
      <news:keywords>Amy Shen, China, HSG, Jiangsu, Jiangyin, PeierTech, Sequoia China, Steve Jia</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Medical-Devices.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/glooko-reports-no-severe-hypoglycaemia-in-267-patient-endotool-iv-labour-and-delivery-analysis/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T04:10:16+00:00</news:publication_date>
      <news:title>Glooko reports no severe hypoglycaemia in 267-patient EndoTool IV labour and delivery analysis</news:title>
      <news:keywords>Advocate Health, Diabetes Technology Society, EndoTool IV, EndoTool IV Cloud, GestationalCare, Glooko Inc., Joseph Aloi, Mark Clements, Mike Alvarez, United States Food and Drug Administration, Wake Forest University School of Medicine</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/ono-pharmaceuticals-ono-1110-missed-three-pain-trial-endpoints-so-why-is-the-drug-still-moving-forward/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T04:01:32+00:00</news:publication_date>
      <news:title>Ono Pharmaceutical’s ONO-1110 missed three pain trial endpoints, so why is the drug still moving forward?</news:title>
      <news:keywords>Japan, Ltd., Ono Pharmaceutical Co., ONO-1110, ONO-1110-04, ONO-1110-05, ONO-1110-06, ONO-1110-07, ONO-1110-08, Osaka</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2026/08/PDN-Generic-Image.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://pharmadevicenews.com/pythia-labs-launches-ai-antibody-platform-after-generating-binders-against-15-of-22-therapeutic-targets/</loc>
    <news:news>
      <news:publication>
        <news:name>PharmaDeviceNews</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-30T03:53:25+00:00</news:publication_date>
      <news:title>Pythia Labs launches AI antibody platform after generating binders against 15 of 22 therapeutic targets</news:title>
      <news:keywords>CCR8, CXCR4, IL11, Joshua Laniado, Los Angeles, MRGPRX2, Pythia Labs, Pythia-1, San Diego, Todd O. Yeates</news:keywords>
    </news:news>
    <image:image>
      <image:loc>https://pharmadevicenews.com/wp-content/uploads/2025/12/pharmadevicenews-1.png</image:loc>
    </image:image>
  </url>
</urlset>